Credit Suisse’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $3.8M | Sell |
322,544
-3,673
| -1% | -$47K | ﹤0.01% | 1458 |
|
|
2023
Q4 | $4.63M | Sell |
326,217
-95
| -0% | -$1.08K | ﹤0.01% | 1378 |
|
|
2023
Q3 | $3.97M | Sell |
326,312
-32,340
| -9% | -$417K | ﹤0.01% | 1401 |
|
|
2023
Q2 | $4.5M | Buy |
358,652
+67,238
| +23% | +$798K | ﹤0.01% | 1405 |
|
|
2023
Q1 | $3.23M | Buy |
291,414
+15,662
| +6% | +$193K | ﹤0.01% | 1588 |
|
|
2022
Q4 | $3.37M | Buy |
275,752
+6,606
| +2% | +$74.4K | ﹤0.01% | 1567 |
|
|
2022
Q3 | $2.81M | Buy |
269,146
+13,768
| +5% | +$153K | ﹤0.01% | 1624 |
|
|
2022
Q2 | $2.74M | Sell |
255,378
-13,785
| -5% | -$114K | ﹤0.01% | 1683 |
|
|
2022
Q1 | $2.55M | Buy |
269,163
+33,960
| +14% | +$318K | ﹤0.01% | 1921 |
|
|
2021
Q4 | $2.72M | Sell |
235,203
-10,113
| -4% | -$113K | ﹤0.01% | 2541 |
|
|
2021
Q3 | $2.34M | Sell |
245,316
-21,758
| -8% | -$223K | ﹤0.01% | 2699 |
|
|
2021
Q2 | $2.58M | Buy |
267,074
+2,014
| +0.8% | +$19.7K | ﹤0.01% | 2647 |
|
|
2021
Q1 | $2.62M | Sell |
265,060
-142,326
| -35% | -$2.2M | ﹤0.01% | 2614 |
|
|
2020
Q4 | $9.41M | Buy |
407,386
+67,857
| +20% | +$1.39M | ﹤0.01% | 1621 |
|
|
2020
Q3 | $4.79M | Sell |
339,529
-126,794
| -27% | -$1.85M | ﹤0.01% | 1812 |
|
|
2020
Q2 | $7.03M | Buy |
466,323
+170,039
| +57% | +$2.07M | 0.01% | 1492 |
|
|
2020
Q1 | $2.74M | Sell |
296,284
-40,704
| -12% | -$387K | ﹤0.01% | 1922 |
|
|
2019
Q4 | $3.28M | Buy |
336,988
+133,559
| +66% | +$1.22M | ﹤0.01% | 2205 |
|
|
2019
Q3 | $1.63M | Buy |
203,429
+7,134
| +4% | +$77.4K | ﹤0.01% | 2632 |
|
|
2019
Q2 | $2.45M | Buy |
196,295
+30,434
| +18% | +$386K | ﹤0.01% | 2306 |
|
|
2019
Q1 | $2.25M | Sell |
165,861
-30,498
| -16% | -$373K | ﹤0.01% | 2287 |
|
|
2018
Q4 | $1.88M | Buy |
196,359
+11,153
| +6% | +$123K | ﹤0.01% | 2294 |
|
|
2018
Q3 | $2.24M | Sell |
185,206
-32,215
| -15% | -$451K | ﹤0.01% | 2275 |
|
|
2018
Q2 | $3.4M | Sell |
217,421
-305,048
| -58% | -$4.61M | ﹤0.01% | 2032 |
|
|
2018
Q1 | $7.86M | Sell |
522,469
-163,372
| -24% | -$2.49M | 0.01% | 1404 |
|
|
2017
Q4 | $9.87M | Sell |
685,841
-227,901
| -25% | -$3.13M | 0.01% | 1300 |
|
|
2017
Q3 | $13.8M | Buy |
913,742
+759,307
| +492% | +$10M | 0.01% | 1061 |
|
|
2017
Q2 | $1.55M | Sell |
154,435
-139,400
| -47% | -$1.12M | ﹤0.01% | 2397 |
|
|
2017
Q1 | $2.1M | Buy |
293,835
+108,906
| +59% | +$689K | ﹤0.01% | 2321 |
|
|
2016
Q4 | $918K | Buy |
184,929
+38,966
| +27% | +$270K | ﹤0.01% | 3089 |
|
|
2016
Q3 | $1.08M | Sell |
145,963
-41,848
| -22% | -$283K | ﹤0.01% | 2893 |
|
|
2016
Q2 | $1.03M | Buy |
187,811
+30,541
| +19% | +$214K | ﹤0.01% | 2899 |
|
|
2016
Q1 | $1.33M | Buy |
157,270
+42,254
| +37% | +$299K | ﹤0.01% | 2514 |
|
|
2015
Q4 | $1.11M | Buy |
115,016
+51,238
| +80% | +$462K | ﹤0.01% | 2738 |
|
|
2015
Q3 | $892K | Sell |
63,778
-152,978
| -71% | -$2.4M | ﹤0.01% | 2914 |
|
|
2015
Q2 | $3.07M | Sell |
216,756
-48,962
| -18% | -$589K | ﹤0.01% | 2194 |
|
|
2015
Q1 | $2.89M | Buy |
265,718
+90,612
| +52% | +$799K | ﹤0.01% | 2087 |
|
|
2014
Q4 | $1.46M | Buy |
175,106
+78,354
| +81% | +$538K | ﹤0.01% | 2822 |
|
|
2014
Q3 | $576K | Buy |
96,752
+56,667
| +141% | +$297K | ﹤0.01% | 3533 |
|
|
2014
Q2 | $134K | Sell |
40,085
-39,507
| -50% | -$92.7K | ﹤0.01% | 4487 |
|
|
2014
Q1 | $165K | Buy |
79,592
+2,068
| +3% | +$5.17K | ﹤0.01% | 4414 |
|
|
2013
Q4 | $183K | Buy |
77,524
+19,264
| +33% | +$42.3K | ﹤0.01% | 4361 |
|
|
2013
Q3 | $135K | Sell |
58,260
-50,881
| -47% | -$128K | ﹤0.01% | 4063 |
|
|
2013
Q2 | $254K | Buy |
+109,141
| New | +$335K | ﹤0.01% | 3728 |
|
Other funds holding FOLD
PA
ACA
RG
Credit Suisse's FOLD Position: Q1 2024 in Review
Credit Suisse reduced its Amicus Therapeutics (FOLD) stake by 1.1% in Q1 2024, selling an estimated $47K and leaving 322,544 shares worth $3.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1458.
Credit Suisse first reported a position in FOLD in Q2 2013 and has held it in 44 quarters since. The position peaked at $13.8M in Q3 2017. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.
- Credit Suisse held 322,544 shares of Amicus Therapeutics worth $3.8M as of Q1 2024.
- Credit Suisse sold 3,673 Amicus Therapeutics shares in Q1 2024, an estimated $47K.
- Amicus Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1458 holding.
- Credit Suisse first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Amicus Therapeutics position peaked at $13.8M in Q3 2017.
- 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.